See more : Borr Drilling Limited (BORR.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Luoxin Pharmaceuticals Group Stock Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- HUB Cyber Security Ltd. (HUBCZ) Income Statement Analysis – Financial Results
- Vow ASA (VOW.OL) Income Statement Analysis – Financial Results
- Hefei Urban Construction Development Co., Ltd (002208.SZ) Income Statement Analysis – Financial Results
- Griffon Corporation (GFF) Income Statement Analysis – Financial Results
- China Minsheng Banking Corp., Ltd. (1988.HK) Income Statement Analysis – Financial Results
Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)
About Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers medical treatment and health services. The company was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. Luoxin Pharmaceuticals Group Stock Co., Ltd. is based in Linyi, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.36B | 3.59B | 6.48B | 6.10B | 7.59B | 935.45M | 828.04M | 637.40M | 584.21M | 537.33M | 474.17M | 474.64M | 423.43M |
| Cost of Revenue | 1.34B | 2.63B | 3.23B | 2.83B | 2.80B | 692.62M | 575.82M | 454.13M | 414.15M | 388.30M | 360.84M | 364.24M | 336.47M |
| Gross Profit | 1.02B | 959.34M | 3.25B | 3.27B | 4.79B | 242.82M | 252.22M | 183.27M | 170.06M | 149.03M | 113.33M | 110.40M | 86.96M |
| Gross Profit Ratio | 43.33% | 26.74% | 50.19% | 53.64% | 63.11% | 25.96% | 30.46% | 28.75% | 29.11% | 27.74% | 23.90% | 23.26% | 20.54% |
| Research & Development | 112.27M | 204.73M | 320.95M | 361.27M | 419.99M | 33.35M | 30.95M | 24.29M | 22.30M | 21.56M | 16.39M | 78.06M | 0.00 |
| General & Administrative | 138.71M | 124.70M | 96.64M | 101.92M | 94.75M | 12.58M | 15.56M | 10.86M | 9.72M | 9.35M | 7.49M | 33.79M | 29.47M |
| Selling & Marketing | 964.01M | 1.73B | 1.87B | 2.00B | 3.25B | 26.66M | 20.93M | 18.24M | 15.92M | 13.86M | 9.71M | 10.41M | 7.82M |
| SG&A | 1.39B | 1.85B | 1.96B | 2.10B | 3.34B | 39.24M | 36.49M | 29.10M | 25.63M | 23.20M | 17.19M | 44.20M | 37.28M |
| Other Expenses | 105.64M | 312.72M | 285.59M | 252.24M | 220.71M | -241.68K | -98.81K | 2.57M | 3.63M | 4.02M | 1.03M | 261.82K | -240.61K |
| Operating Expenses | 1.61B | 2.37B | 2.57B | 2.72B | 3.98B | 114.45M | 106.11M | 83.01M | 71.35M | 64.12M | 49.51M | 46.45M | 39.04M |
| Cost & Expenses | 2.95B | 5.00B | 5.80B | 5.54B | 6.78B | 807.07M | 681.94M | 537.13M | 485.50M | 452.41M | 410.35M | 410.69M | 375.51M |
| Interest Income | 8.43M | 14.66M | 10.16M | 13.43M | 7.98M | 1.74M | 652.32K | 289.54K | 127.15K | 353.61K | 303.43K | 8.37M | -0.35 |
| Interest Expense | 75.97M | 122.67M | 105.18M | 50.37M | 46.83M | 4.14M | 716.60K | 2.16M | 3.08M | 1.53M | 2.93M | 0.00 | 5.25M |
| Depreciation & Amortization | 222.54M | 273.37M | 212.24M | 184.18M | 170.06M | 139.50M | 21.25M | 15.51M | 10.06M | 8.40M | 8.17M | 1.55M | 7.46M |
| EBITDA | -320.09M | -1.06B | 790.16M | 642.69M | 942.36M | 723.43M | 157.12M | 134.57M | 101.83M | 80.02M | 59.60M | 63.95M | 49.12M |
| EBITDA Ratio | -13.54% | -28.44% | 13.87% | 11.78% | 12.83% | 17.79% | 19.21% | 20.98% | 20.19% | 18.77% | 14.90% | 13.51% | 11.60% |
| Operating Income | -490.15M | -1.41B | 698.96M | 425.74M | 725.06M | 127.70M | 133.66M | 113.85M | 90.98M | 70.15M | 52.13M | 62.57M | 41.66M |
| Operating Income Ratio | -20.74% | -39.38% | 10.79% | 6.98% | 9.55% | 13.65% | 16.14% | 17.86% | 15.57% | 13.06% | 10.99% | 13.18% | 9.84% |
| Total Other Income/Expenses | -129.82M | -4.01M | -213.76M | -16.81M | -852.69K | 4.50M | -98.81K | 2.28M | 3.62M | 4.02M | -6.58M | 261.82K | -427.88K |
| Income Before Tax | -619.97M | -1.46B | 485.20M | 408.93M | 724.21M | 127.46M | 133.56M | 116.13M | 94.60M | 74.17M | 53.03M | 62.83M | 41.23M |
| Income Before Tax Ratio | -26.23% | -40.78% | 7.49% | 6.71% | 9.54% | 13.63% | 16.13% | 18.22% | 16.19% | 13.80% | 11.18% | 13.24% | 9.74% |
| Income Tax Expense | 164.81M | -204.95M | 63.55M | 66.33M | 70.46M | 16.12M | 17.71M | 15.77M | 12.81M | 10.21M | 7.07M | 9.16M | 8.71M |
| Net Income | -661.14M | -1.26B | 406.10M | 320.70M | 633.95M | 111.35M | 115.85M | 100.36M | 81.79M | 63.96M | 45.96M | 53.67M | 32.52M |
| Net Income Ratio | -27.97% | -35.07% | 6.27% | 5.26% | 8.35% | 11.90% | 13.99% | 15.75% | 14.00% | 11.90% | 9.69% | 11.31% | 7.68% |
| EPS | -0.61 | -0.88 | 0.28 | 0.22 | 1.76 | 0.10 | 0.34 | 0.32 | 0.32 | 0.25 | 0.18 | 0.21 | 0.17 |
| EPS Diluted | -0.61 | -0.88 | 0.28 | 0.22 | 0.57 | 0.10 | 0.34 | 0.32 | 0.32 | 0.25 | 0.18 | 0.21 | 0.17 |
| Weighted Avg Shares Out | 1.08B | 1.43B | 1.46B | 1.46B | 359.70M | 1.07B | 339.57M | 310.21M | 255.12M | 255.84M | 256.19M | 253.42M | 1.46B |
| Weighted Avg Shares Out (Dil) | 1.08B | 1.43B | 1.46B | 1.46B | 359.70M | 1.07B | 339.57M | 310.21M | 255.12M | 255.84M | 256.19M | 253.42M | 1.46B |
Source: https://incomestatements.info
Category: Stock Reports